Loading
Actinium Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by O'Loughlin Steve, was filed 10 Dec 2018.
Actinium Pharmaceuticals, Inc.: what insiders have been doing
Actinium Pharmaceuticals, Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). From 20 October 2025 to 20 October 2026, the disclosure feed for Actinium Pharmaceuticals, Inc. logged 8 filings by 7 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Insider buying of Actinium Pharmaceuticals, Inc. has been absent for the past year. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4.
For context, the typical company on the same exchange (median of 5,453 companies) published 22 filings over the same period, against 8 filings here. Looking back to 2016, when coverage begins, insiders filed 26 purchases and 119 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 90,000 USD and net income at -33.9 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Vivos Inc and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
162
Thresholds
n/a
Buy Volume
€148,905
26 ops. · all time
Sell Volume
€2M
119 ops. · all time
Since the insiders bought
- -52.3%Entry US$13.20 · Close at T+365 US$6.30
- -52.3%Entry US$13.20 · Close at T+365 US$6.30
- -51.4%Entry US$13.26 · Close at T+365 US$6.45
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,348 of 26,281 companies
26.6
score / 100
Value3
Quality50
FCF yld-56%
Earn yld-77%
EV/EBITDA·
ROE46%
Gross mgn0.0%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.13
Analyst consensus
5 analysts1.75/5
US$2.00Target US$3.60(+219%)US$5.00
Income statement
RevenueUS$90k
EBITDA-US$35.4M-39362% margin
Net income-US$33.9M32.2% margin
Valuation
PER (trailing)3.1x
PER (forward)-2.2x
P/Book1.2x
Beta0.27
Balance sheet & cash
Market capUS$35.5M
Total debtUS$1.7M
Free Cash Flow-US$24.7M
Debt / Equity4%
Profitability & ownership
ROE45.9%
ROA11.6%
% insiders8.1%
% institutions17.3%
Last declaration on 16 October 2026
Declarations162 total
250,000 shares0Common StockSEC:0001213900-26-110340:0
1,027,274 shares0Common StockSEC:0001213900-26-097741:1
18,000 shares0Common StockSEC:0001213900-26-097742:0
61,600 shares0Common StockSEC:0001213900-26-097744:0
62,800 shares0Common StockSEC:0001213900-26-097745:0
61,600 shares0Common StockSEC:0001213900-26-097739:0
62,800 shares0Common StockSEC:0001213900-26-097740:0
753,600 shares0Common StockSEC:0001213900-26-097741:0
120,900 shares@ US$1.71100.0% of flowCommon StockSEC:0001213900-25-079019:0
300,000 shares0Common StockSEC:0001213900-22-049737:0
3,500 shares@ US$0.60100.0% of flowCommon StockSEC:0001213900-19-003738:0
8,125 shares@ US$0.602.2% of flowCommon StockSEC:0001213900-19-002982:0
10,000 shares@ US$0.43529.2% of flowCommon StockSEC:0001213900-18-017143:0
Canonical exit: 10 Mar 2019 (T+90)
10,000 shares@ US$0.43721.8% of flowCommon StockSEC:0001213900-18-017145:0
Canonical exit: 10 Mar 2019 (T+90)
10,000 shares@ US$0.4499100.0% of flowCommon StockSEC:0001213900-18-016321:0
Canonical exit: 17 Feb 2019 (T+90)
10,000 shares@ US$0.792.9% of flowCommon stockSEC:0001213900-18-009317:0
Canonical exit: 15 Oct 2018 (T+90)
12,000 shares@ US$0.5031.0% of flowCommon StockSEC:0001213900-18-007754:0
Canonical exit: 13 Sept 2018 (T+90)
5,000 shares@ US$0.38Common StockSEC:0001213900-18-004773:0
Canonical exit: 18 Jul 2018 (T+90)
14,000 shares@ US$0.50Common StockSEC:0001213900-18-003155:0
52,500 shares@ US$0.50Common StockSEC:0001213900-18-002739:0
10,000 shares@ US$0.50Common StockSEC:0001213900-18-002726:0
7,000 shares@ US$0.50Common StockSEC:0001213900-18-002730:0
10,000 shares@ US$0.50Common StockSEC:0001213900-18-002737:0
22,730 shares@ US$0.43Common stockSEC:0001213900-18-002433:0
Canonical exit: 29 May 2018 (T+90)
33,333 shares@ US$0.75Common StockSEC:0001213900-17-008254:0
Canonical exit: 31 Oct 2017 (T+90)
25 of 162 declarations
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. It employs innovative approaches based on radioimmunotherapy.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
